XENETIC BIOSCIENCES INC
NASDAQ
US Flag
XBIO

XBIO
XENETIC BIOSCIENCES INC
US Flag
NASDAQ
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

XBIO Stock Chart

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 7
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovery, research and development of biologic drugs and novel oncology therapeutics. The Company’s lead investigational product candidate is oncology therapeutic XBIO-101, which is used for the treatment of progestin - resistant endometrial cancer. The Company is currently conducting a Phase 2 trial for XBIO-101. The Company’s lead proprietary technology is PolyXen, which enables platform technology that can be applied to protein or peptide therapeutics using the natural polymer polysialic acid. The Company’s technology includes XBIO-101, PolyXen, OncoHist, ErepoXen and ImuXen. ErepoXen or polysialylated erythropoietin is an internal drug candidate which uses the company’s PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out